In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1062-1066

  Rybak, Michael J ^a,b   Hershberger, Ellie ^a   Moldovan, Tabitha ^a   Grucz, Richard G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; OXAZOLES; OXAZOLIDINONES; STAPHYLOCOCCUS; TIME FACTORS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0034018950     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1062-1066.2000     Document Type: Article

References (11)

1. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
2. Allen, N. E., W. E. Alborn, Jr., and J. N. Hobbs, Jr. 1991. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. 35:2639-2642.
3. Allen, N. E., J. N. Hobbs, and W. E. Alborn. 1987. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. 31:1093-1099.
4. Bush, L. M., J. A. Boscia, and D. Kaye. 1988. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 32:877-881.
5. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering, Jr. 1986. In vitro and in vivo activity of LY146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
6. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
7. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of LY146032, a new lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31:625-629.
8. Kaatz, G. W., S. M. Sen, V. N. Reddy, E. M. Bailey, and M. J. Rybak. 1990. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:2081-2085.
9. Lamp, K. C., and M. J. Rybak. 1993. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob. Agents Chemother. 37:605-609.
10. National Committee for Clinical Laboratory Standards. 1998. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Rybak, M. J., E. M. Bailey, K. C. Lamp, and G. W. Kaatz. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.